The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone; certain myelodysplastic syndromes; and mantle cell lymphoma following specific prior treatment.
Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients.
On a consolidated basis, net profit of Natco Pharma rose 28.23% to Rs 80.40 crore on 57.80% rise in net sales to Rs 560.50 crore in Q3 December 2021 over Q3 December 2020.